This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 114/7/637    most recent CIRCULATIONAHA.106.639831v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hsieh, P. C.H. Articles by Lee, R. T. Search for Related Content PubMed PubMed Citation Articles by Hsieh, P. C.H. Articles by Lee, R. T. Related Collections Other heart failure Related Article

(Circulation. 2006;114:637-644.)
© 2006 American Heart Association, Inc.

Heart Failure

Local Controlled Intramyocardial Delivery of Platelet-Derived Growth Factor Improves Postinfarction Ventricular Function Without Pulmonary Toxicity

Patrick C.H. Hsieh, MD, PhD; Catherine MacGillivray, AD; Joseph Gannon;; Francisco U. Cruz, MS; Richard T. Lee, MD

From the Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, Mass.

Correspondence to Richard T. Lee, MD, Partners Research Facility, 65 Landsdowne St, Cambridge, MA 02139. E-mail rlee{at}rics.bwh.harvard.edu

Received May 12, 2006; revision received June 5, 2006; accepted June 12, 2006.

Background— Local delivery methods can target therapies to specific tissues and potentially avoid toxicity to other organs. Platelet-derived growth factor can protect the myocardium, but it also plays an important role in promoting pulmonary hypertension. It is not known whether local myocardial delivery of platelet-derived growth factor during myocardial infarction (MI) can lead to sustained cardiac benefit without causing pulmonary hypertension.

Methods and Results— We performed a randomized and blinded experiment of 127 rats that survived experimental MI or sham surgery. We delivered platelet-derived growth factor (PDGF)-BB with self-assembling peptide nanofibers (NFs) to provide controlled release within the myocardium. There were 6 groups with n20 in each group: sham, sham+NF, sham+NF/PDGF, MI, MI+NF, and MI+NF/PDGF. Serial echocardiography from 1 day to 3 months showed significant improvement of ventricular fractional shortening, end-systolic dimension, and end-diastolic dimension with local PDGF delivery (P<0.05 for MI+NF/PDGF versus MI or MI+NF). Catheterization at 4 months revealed improved ventricular function in the controlled delivery group (left ventricular end-diastolic pressure, cardiac index, +dP/dt, –dP/dt, and time constant of exponential decay all P<0.05 for MI+NF/P versus MI or MI+NF). Infarcted myocardial volume was reduced by NF/PDGF therapy (34.0±13.3% in MI, 28.9±12.9% in MI+NF, and 12.0±5.8% in MI+NF/PDGF; P<0.001). There was no evidence of pulmonary toxicity from the therapy, with no differences in right ventricular end-systolic pressure, right ventricular dP/dt, bromodeoxyuridine staining, or pulmonary artery medial wall thickness.

Conclusions— Intramyocardial delivery of PDGF by self-assembling peptide NFs leads to long-term improvement in cardiac performance after experimental infarction without apparent pulmonary toxicity. Local myocardial protection may allow prevention of heart failure without systemic toxicity.

---

 

CLINICAL PERSPECTIVE

Related Article:

Issue Highlights
Circulation 2006 114: 615. [Extract] [Full Text]

This article has been cited by other articles:

				K. Seki, S. Sanada, A. Y. Kudinova, M. L. Steinhauser, V. Handa, J. Gannon;, and R. T. Lee Interleukin-33 Prevents Apoptosis and Improves Survival After Experimental Myocardial Infarction Through ST2 Signaling Circ Heart Fail, November 1, 2009; 2(6): 684 - 691. [Abstract] [Full Text] [PDF]

				M. Schmidinger and C. C. Zielinski Reply to A. Bamias et al J. Clin. Oncol., May 20, 2009; 27(15): 2569 - 2570. [Full Text] [PDF]

				C.-H. Chen, H.-J. Wei, W.-W. Lin, I. Chiu, S.-M. Hwang, C.-C. Wang, W.-Y. Lee, Y. Chang, and H.-W. Sung Porous tissue grafts sandwiched with multilayered mesenchymal stromal cell sheets induce tissue regeneration for cardiac repair Cardiovasc Res, October 1, 2008; 80(1): 88 - 95. [Abstract] [Full Text] [PDF]

				M. H. Chen, R. Kerkela, and T. Force Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics Circulation, July 1, 2008; 118(1): 84 - 95. [Full Text] [PDF]

				C.-C. Wang, C.-H. Chen, W.-W. Lin, S.-M. Hwang, P. C.H. Hsieh, P.-H. Lai, Y.-C. Yeh, Y. Chang, and H.-W. Sung Direct intramyocardial injection of mesenchymal stem cell sheet fragments improves cardiac functions after infarction Cardiovasc Res, February 1, 2008; 77(3): 515 - 524. [Abstract] [Full Text] [PDF]